Manuel J Cuesta1, Ana M Sánchez-Torres2, Bibiana Cabrera3, Miquel Bioque3, Jessica Merchán-Naranjo4, Iluminada Corripio5, Ana González-Pinto6, Antonio Lobo7, Igor Bombín8, Elena de la Serna9, Julio Sanjuan10, Mara Parellada4, Jerónimo Saiz-Ruiz11, Miquel Bernardo12. 1. Department of Psychiatry, Complejo Hospitalario de Navarra, Pamplona, Spain; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain. Electronic address: mcuestaz@cfnavarra.es. 2. Department of Psychiatry, Complejo Hospitalario de Navarra, Pamplona, Spain; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain. 3. Barcelona Clinic Schizophrenia Unit, Neuroscience Institute, Hospital Clinic of Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain. 4. Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Child and Adolescent Psychiatry Department, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IiSGM, CIBERSAM. Madrid, Spain. 5. Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Department of Psychiatry, Institut d'Investigació Biomèdica-Sant Pau (IIB-SANT PAU), Hospital de la Santa Creu i Sant Pau, Barcelona; Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. 6. Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Department of Psychiatry, Hospital Universitario de Álava, University of the Basque Country, Vitoria, Spain. 7. Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Instituto de Investigación Sanitaria de Aragón (IIS Aragón). University of Zaragoza, Spain. 8. Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Reintegra Foundation, Oviedo, Spain. 9. Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Department of Child and Adolescent Psychiatry and Psychology, Institut Clínic de Neurociències. Hospital Clínic Universitari, Barcelona, Spain. 10. Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Clinic Hospital (INCLIVA), Valencia, Spain. 11. Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Psychiatry Department, Instituto Ramón y Cajal de Investigación Sanitaria (IRyCIS), Hospital Ramón y Cajal, Universidad de Alcalá, Madrid, Spain. 12. Barcelona Clinic Schizophrenia Unit, Neuroscience Institute, Hospital Clinic of Barcelona, Spain; Department of Psychiatry and Clinical Psychobiology, University of Barcelona. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain.
Abstract
BACKGROUND: The extent to which socio-demographic, clinical, and premorbid adjustment variables contribute to cognitive deficits in first-episode schizophrenia spectrum disorders remains to be ascertained. AIMS: To examine the pattern and magnitude of cognitive impairment in first-episode psychosis patients, the profile of impairment across psychosis subtypes and the associations with premorbid adjustment. METHODS: 226 first-episode psychosis patients and 225 healthy controls were assessed in the PEPsCog study, as part of the PEPs study. RESULTS: Patients showed slight to moderate cognitive impairment, verbal memory being the domain most impaired compared to controls. Broad affective spectrum patients had better premorbid IQ and outperformed the schizophrenia and other psychosis groups in executive function, and had better global cognitive function than the schizophrenia group. Adolescent premorbid adjustment together with age, gender, parental socio-economic status, and mean daily antipsychotic doses were the factors that best explained patients' cognitive performance. General and adolescent premorbid adjustment, age and parental socio-economic status were the best predictors of cognitive performance in controls. CONCLUSIONS: Poorer premorbid adjustment together with socio-demographic factors and higher daily antipsychotic doses were related to a generalized cognitive impairment and to a lower premorbid intellectual reserve, suggesting that neurodevelopmental impairment was present before illness onset.
BACKGROUND: The extent to which socio-demographic, clinical, and premorbid adjustment variables contribute to cognitive deficits in first-episode schizophrenia spectrum disorders remains to be ascertained. AIMS: To examine the pattern and magnitude of cognitive impairment in first-episode psychosispatients, the profile of impairment across psychosis subtypes and the associations with premorbid adjustment. METHODS: 226 first-episode psychosispatients and 225 healthy controls were assessed in the PEPsCog study, as part of the PEPs study. RESULTS:Patients showed slight to moderate cognitive impairment, verbal memory being the domain most impaired compared to controls. Broad affective spectrum patients had better premorbid IQ and outperformed the schizophrenia and other psychosis groups in executive function, and had better global cognitive function than the schizophrenia group. Adolescent premorbid adjustment together with age, gender, parental socio-economic status, and mean daily antipsychotic doses were the factors that best explained patients' cognitive performance. General and adolescent premorbid adjustment, age and parental socio-economic status were the best predictors of cognitive performance in controls. CONCLUSIONS: Poorer premorbid adjustment together with socio-demographic factors and higher daily antipsychotic doses were related to a generalized cognitive impairment and to a lower premorbid intellectual reserve, suggesting that neurodevelopmental impairment was present before illness onset.
Authors: Ana M Sánchez-Torres; María Rosa Elosúa; Ruth Lorente-Omeñaca; Lucía Moreno-Izco; Victor Peralta; Joseph Ventura; Manuel J Cuesta Journal: Eur Arch Psychiatry Clin Neurosci Date: 2016-06-06 Impact factor: 5.270
Authors: Daniel Bergé; Anna Mané; Tyler A Lesh; Miquel Bioque; Fe Barcones; Ana Maria Gonzalez-Pinto; Mara Parellada; Eduard Vieta; Josefina Castro-Fornieles; Roberto Rodriguez-Jimenez; Maria Paz García-Portilla; Judith Usall; Cameron S Carter; Bibiana Cabrera; Miguel Bernardo; Joost Janssen Journal: Schizophr Bull Date: 2020-07-08 Impact factor: 9.306
Authors: A M Sánchez-Torres; L Moreno-Izco; R Lorente-Omeñaca; B Cabrera; A Lobo; A M González-Pinto; J Merchán-Naranjo; I Corripio; E Vieta; E de la Serna; A Butjosa; F Contreras; S Sarró; G Mezquida; M Ribeiro; M Bernardo; M J Cuesta Journal: Eur Arch Psychiatry Clin Neurosci Date: 2017-11-21 Impact factor: 5.270
Authors: Laura Ferraro; Caterina La Cascia; Diego Quattrone; Lucia Sideli; Domenica Matranga; Veronica Capuccio; Giada Tripoli; Charlotte Gayer-Anderson; Craig Morgan; Musa B Sami; Pak Sham; Lieuwe de Haan; Eva Velthorst; Hannah E Jongsma; James B Kirkbride; Bart P F Rutten; Alexander L Richards; Laura Roldan; Celso Arango; Miquel Bernardo; Julio Bobes; Julio Sanjuan; Jose Luis Santos; Manuel Arrojo; Ilaria Tarricone; Andrea Tortelli; Andrei Szöke; Cristina Marta Del-Ben; Jean-Paul Selten; Michael Lynskey; Peter B Jones; Jim Van Os; Daniele La Barbera; Robin M Murray; Marta Di Forti Journal: Schizophr Bull Date: 2020-04-10 Impact factor: 9.306
Authors: Johanna Seitz-Holland; Suheyla Cetin-Karayumak; Matcheri Keshavan; Marek Kubicki; Joanne D Wojcik; Amanda Lyall; James Levitt; Martha E Shenton; Ofer Pasternak; Carl-Fredrik Westin; Madhura Baxi; Sinead Kelly; Raquelle Mesholam-Gately; Mark Vangel; Godfrey Pearlson; Carol A Tamminga; John A Sweeney; Brett A Clementz; David Schretlen; Petra Verena Viher; Katharina Stegmayer; Sebastian Walther; Jungsun Lee; Tim Crow; Anthony James; Aristotle Voineskos; Robert W Buchanan; Philip R Szeszko; Anil K Malhotra; Yogesh Rathi Journal: Mol Psychiatry Date: 2021-01-22 Impact factor: 13.437
Authors: Lawrence H Yang; Bernalyn Ruiz; Amar D Mandavia; Margaux M Grivel; Liang Y Wong; Michael R Phillips; Matcheri S Keshavan; Huijun Li; Jeffrey A Lieberman; Ezra Susser; Larry J Seidman; William S Stone Journal: Schizophr Res Date: 2020-04-05 Impact factor: 4.939